Neuralstem Stock Price, News & Analysis (NASDAQ:CUR)

$1.06 0.05 (4.95 %)
(As of 11/17/2017 02:13 PM ET)
Previous Close$1.06
Today's Range$0.97 - $1.09
52-Week Range$0.88 - $6.60
Volume317,444 shs
Average Volume317,789 shs
Market Capitalization$16.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.6

About Neuralstem (NASDAQ:CUR)

Neuralstem logoNeuralstem, Inc. (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform. The Company's technology allows the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the treatment of central nervous system diseases and conditions. The Company is developing NSI-189 for the treatment of major depressive disorder (MDD) and other psychiatric and/or cognitive impairment indications associated with hippocampal atrophy. The Company's NSI-566 is indicated for amyotrophic lateral sclerosis (ALS), chronic spinal cord injury and motor deficits due to ischemic stroke.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Sector: Pharmaceuticals - NEC
  • Symbol: NASDAQ:CUR
  • CUSIP: N/A
  • Web: www.neuralstem.com
Debt:
  • Current Ratio: 8.03%
  • Quick Ratio: 8.03%
Sales & Book Value:
  • Annual Sales: $20,000.00
  • Price / Sales: 802.95
  • Book Value: $0.76 per share
  • Price / Book: 1.39
Profitability:
  • Trailing EPS: ($1.66)
  • Net Income: ($21,070,000.00)
  • Net Margins: -154,347.81%
  • Return on Equity: -148.94%
  • Return on Assets: -84.85%
Misc:
  • Employees: 11
  • Outstanding Shares: 15,150,000
 

Frequently Asked Questions for Neuralstem (NASDAQ:CUR)

What is Neuralstem's stock symbol?

Neuralstem trades on the NASDAQ under the ticker symbol "CUR."

How were Neuralstem's earnings last quarter?

Neuralstem, Inc. (NASDAQ:CUR) released its earnings results on Tuesday, August, 8th. The company reported ($0.39) earnings per share for the quarter, topping the Zacks' consensus estimate of ($9.49) by $9.10. Neuralstem had a negative net margin of 154,347.81% and a negative return on equity of 148.94%. View Neuralstem's Earnings History.

Where is Neuralstem's stock going? Where will Neuralstem's stock price be in 2017?

0 brokerages have issued 12-month price objectives for Neuralstem's stock. Their forecasts range from $3.18 to $3.18. On average, they anticipate Neuralstem's share price to reach $3.18 in the next year. View Analyst Ratings for Neuralstem.

Who are some of Neuralstem's key competitors?

Who are Neuralstem's key executives?

Neuralstem's management team includes the folowing people:

  • Richard J. Daly, Chairman of the Board, President, Chief Executive Officer, Interim Principal Financial and Accounting Officer (Age 64)
  • David Recker M.D., Chief Medical Officer (Age 58)
  • Cristina Csimma, Director
  • Zhuo Zhang, Director
  • Scott V. Ogilvie, Independent Director (Age 61)
  • William Clyde Oldaker, Independent Director (Age 75)
  • Sandford D. Smith, Independent Director (Age 70)

How do I buy Neuralstem stock?

Shares of Neuralstem can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neuralstem's stock price today?

One share of Neuralstem stock can currently be purchased for approximately $1.06.

How big of a company is Neuralstem?

Neuralstem has a market capitalization of $16.05 million and generates $20,000.00 in revenue each year. The company earns ($21,070,000.00) in net income (profit) each year or ($1.66) on an earnings per share basis. Neuralstem employs 11 workers across the globe.

How can I contact Neuralstem?

Neuralstem's mailing address is 20271 Goldenrod Ln, GERMANTOWN, MD 20876-4064, United States. The company can be reached via phone at +1-301-3664841 or via email at [email protected]


MarketBeat Community Rating for Neuralstem (NASDAQ CUR)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  132 (Vote Outperform)
Underperform Votes:  79 (Vote Underperform)
Total Votes:  211
MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Neuralstem (NASDAQ:CUR)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: $3.18 (200.00% upside)

Consensus Price Target History for Neuralstem (NASDAQ:CUR)

Price Target History for Neuralstem (NASDAQ:CUR)

Analysts' Ratings History for Neuralstem (NASDAQ:CUR)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/16/2017S&P Equity ResearchLower Price Target$3.69 -> $3.18N/AView Rating Details
11/10/2016Roth CapitalReiterated RatingBuy$1.20N/AView Rating Details
11/7/2016AegisInitiated CoverageBuyN/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$4.00N/AView Rating Details
(Data available from 11/18/2015 forward)

Earnings

Earnings History and Estimates Chart for Neuralstem (NASDAQ:CUR)

Earnings by Quarter for Neuralstem (NASDAQ:CUR)

Earnings History by Quarter for Neuralstem (NASDAQ CUR)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2017Q2 2017($9.49)($0.39)ViewN/AView Earnings Details
11/8/2016Q3($0.03)($0.05)ViewN/AView Earnings Details
8/11/2016Q2($0.05)($0.04)$2.50 million$2.50 millionViewN/AView Earnings Details
5/9/2016Q1($0.06)($0.07)ViewN/AView Earnings Details
3/14/2016Q4($0.07)($0.05)ViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.06)ViewN/AView Earnings Details
8/10/2015Q2($0.06)($0.06)ViewN/AView Earnings Details
5/8/2015Q115($0.07)($0.06)$2.92 millionViewN/AView Earnings Details
4/20/2015($0.07)($0.06)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.05)($0.06)$0.01 millionViewN/AView Earnings Details
11/7/2014Q314($0.05)($0.05)$0.01 millionViewN/AView Earnings Details
8/8/2014Q214($0.05)($0.08)$0.10 million$0.01 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.04)$0.35 million$0.00 millionViewN/AView Earnings Details
3/10/2014Q4 2013($0.06)($0.04)ViewN/AView Earnings Details
11/11/2013Q3($0.04)($0.09)ViewN/AView Earnings Details
8/9/2013Q213($0.05)($0.09)$0.08 million$0.00 millionViewN/AView Earnings Details
11/9/2012Q312($0.04)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Neuralstem (NASDAQ:CUR)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Neuralstem (NASDAQ:CUR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Neuralstem (NASDAQ CUR)

Insider Ownership Percentage: 19.25%
Institutional Ownership Percentage: 7.20%
Insider Trades by Quarter for Neuralstem (NASDAQ:CUR)
Insider Trades by Quarter for Neuralstem (NASDAQ:CUR)

Insider Trades by Quarter for Neuralstem (NASDAQ CUR)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/17/2017Richard J DalyCEOBuy7,500$4.00$30,000.00View SEC Filing  
3/24/2017Jones Jonathan Brian LloydCFOBuy5,455$5.50$30,002.50View SEC Filing  
2/24/2017Richard J DalyCEOBuy2,591$3.86$10,001.26View SEC Filing  
1/25/2017Richard J DalyCEOBuy2,841$3.52$10,000.32View SEC Filing  
12/23/2016Richard J DalyCEOBuy32,259$0.31$10,000.29View SEC Filing  
11/25/2016Richard J DalyCEOBuy35,715$0.28$10,000.20View SEC Filing  
10/25/2016Richard J DalyCEOBuy35,715$0.28$10,000.20View SEC Filing  
9/23/2016Richard J DalyCEOBuy31,250$0.32$10,000.00View SEC Filing  
11/16/2015Karl JoheInsiderSell25,000$1.09$27,250.00View SEC Filing  
11/9/2015Karl JoheInsiderSell25,000$1.18$29,500.00View SEC Filing  
11/2/2015Karl JoheInsiderSell25,000$1.17$29,250.00View SEC Filing  
10/26/2015Karl JoheInsiderSell25,000$1.13$28,250.00View SEC Filing  
10/19/2015Karl JoheInsiderSell25,000$1.23$30,750.00View SEC Filing  
10/12/2015Karl JoheInsiderSell25,000$1.31$32,750.00View SEC Filing  
10/5/2015Karl JoheInsiderSell25,000$1.26$31,500.00View SEC Filing  
9/28/2015Karl JoheInsiderSell25,000$1.64$41,000.00View SEC Filing  
9/21/2015Karl JoheInsiderSell25,000$1.52$38,000.00View SEC Filing  
9/2/2014Karl JoheInsiderSell6,000$4.09$24,540.00View SEC Filing  
8/1/2014Karl JoheInsiderSell6,000$2.78$16,680.00View SEC Filing  
7/1/2014Karl JoheInsiderSell6,000$4.17$25,020.00View SEC Filing  
6/2/2014Karl JoheInsiderSell6,000$4.25$25,500.00View SEC Filing  
5/5/2014William Clyde OldakerDirectorBuy15,235$3.50$53,322.50View SEC Filing  
4/22/2014Richard GarrCEOSell7,000$4.25$29,750.00View SEC Filing  
4/1/2014Karl JoheInsiderSell6,000$4.11$24,660.00View SEC Filing  
3/20/2014Karl JoheInsiderSell6,000$4.04$24,240.00View SEC Filing  
10/18/2013Karl JoheInsiderSell10,000$2.44$24,400.00View SEC Filing  
9/20/2013Karl JoheInsiderSell10,000$2.62$26,200.00View SEC Filing  
9/19/2013Karl JoheInsiderSell10,000$2.61$26,100.00View SEC Filing  
8/20/2013Karl JoheInsiderSell20,000$1.55$31,000.00View SEC Filing  
7/22/2013Karl JoheInsiderSell12,800$1.62$20,736.00View SEC Filing  
6/20/2013Karl JoheInsiderSell12,800$1.40$17,920.00View SEC Filing  
6/7/2013Richard GarrCEOSell6,000$1.42$8,520.00View SEC Filing  
5/20/2013Karl JoheInsiderSell12,800$1.51$19,328.00View SEC Filing  
2/25/2013Richard GarrCEOSell12,000$1.15$13,800.00View SEC Filing  
11/20/2012Karl JoheInsiderSell12,800$1.00$12,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Neuralstem (NASDAQ:CUR)

Latest Headlines for Neuralstem (NASDAQ CUR)

Source:
DateHeadline
Contrasting Neuralstem (CUR) and The CompetitionContrasting Neuralstem (CUR) and The Competition
www.americanbankingnews.com - November 18 at 11:14 AM
Neuralstem (CUR) Reports Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at at ACNP MeetingNeuralstem (CUR) Reports Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at at ACNP Meeting
www.streetinsider.com - November 17 at 1:37 PM
Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual MeetingNeuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting
finance.yahoo.com - November 16 at 6:17 PM
Comparing Sophiris Bio (SPHS) & Neuralstem (CUR)Comparing Sophiris Bio (SPHS) & Neuralstem (CUR)
www.americanbankingnews.com - November 14 at 5:18 AM
Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update - GlobeNewswire (press release)Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update - GlobeNewswire (press release)
globenewswire.com - November 13 at 9:13 PM
Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business UpdateNeuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update
finance.yahoo.com - November 13 at 12:41 PM
Neuralstem reports 3Q lossNeuralstem reports 3Q loss
finance.yahoo.com - November 13 at 12:41 PM
ETFs with exposure to Neuralstem, Inc. : November 10, 2017ETFs with exposure to Neuralstem, Inc. : November 10, 2017
finance.yahoo.com - November 10 at 5:35 PM
Neuralstem (CUR) Names Dr. David Recker as Chief Medical Officer - StreetInsider.comNeuralstem (CUR) Names Dr. David Recker as Chief Medical Officer - StreetInsider.com
www.streetinsider.com - November 10 at 7:26 AM
Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 10 at 7:26 AM
Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical OfficerNeuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer
finance.yahoo.com - November 9 at 12:11 AM
Neuralstem, Inc. (CUR) Scheduled to Post Earnings on MondayNeuralstem, Inc. (CUR) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 30 at 10:22 AM
Head to Head Analysis: Neos Therapeutics (NEOS) and Neuralstem (CUR)Head to Head Analysis: Neos Therapeutics (NEOS) and Neuralstem (CUR)
www.americanbankingnews.com - October 20 at 2:10 PM
One Thing To Consider Before Buying Neuralstem Inc (CUR)One Thing To Consider Before Buying Neuralstem Inc (CUR)
finance.yahoo.com - October 17 at 6:24 PM
Neuralstem, Inc. (CUR) Sees Large Drop in Short InterestNeuralstem, Inc. (CUR) Sees Large Drop in Short Interest
www.americanbankingnews.com - October 14 at 2:04 AM
Neuralstem: Stock falls in July on Phase II Miss, Gets 2 New Patents for Neural Stem CellsNeuralstem: Stock falls in July on Phase II Miss, Gets 2 New Patents for Neural Stem Cells
finance.yahoo.com - October 3 at 6:56 AM
Neuralstem Announces the Appointment of Two New Members to the Board of DirectorsNeuralstem Announces the Appointment of Two New Members to the Board of Directors
finance.yahoo.com - September 25 at 4:08 PM
ETFs with exposure to Neuralstem, Inc. : September 22, 2017ETFs with exposure to Neuralstem, Inc. : September 22, 2017
finance.yahoo.com - September 22 at 4:41 PM
ETFs with exposure to Neuralstem, Inc. : September 12, 2017ETFs with exposure to Neuralstem, Inc. : September 12, 2017
finance.yahoo.com - September 11 at 11:28 PM
Intra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers - TheStreet.comIntra-Cellular Leaps; Schizophrenia Drug Shows Less Side Effects-Biotech Movers - TheStreet.com
www.thestreet.com - September 7 at 10:45 PM
Neuralstem (CUR) Reports Issuance of Two US Patents - StreetInsider.comNeuralstem (CUR) Reports Issuance of Two US Patents - StreetInsider.com
www.streetinsider.com - September 7 at 10:45 PM
Neuralstem (CUR) Reports Issuance of Two U.S. PatentsNeuralstem (CUR) Reports Issuance of Two U.S. Patents
www.streetinsider.com - September 7 at 5:44 PM
Neuralstem Announces Issuance of Two U.S. PatentsNeuralstem Announces Issuance of Two U.S. Patents
finance.yahoo.com - September 7 at 5:44 PM
ETFs with exposure to Neuralstem, Inc. : August 31, 2017ETFs with exposure to Neuralstem, Inc. : August 31, 2017
finance.yahoo.com - August 31 at 10:34 PM
Neuralstem, Inc. (CUR) Short Interest UpdateNeuralstem, Inc. (CUR) Short Interest Update
www.americanbankingnews.com - August 29 at 1:06 AM
Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017Neuralstem, Inc. :CUR-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
finance.yahoo.com - August 24 at 5:51 PM
Head-To-Head Review: Neuralstem (CUR) & AMAG Pharmaceuticals (AMAG)Head-To-Head Review: Neuralstem (CUR) & AMAG Pharmaceuticals (AMAG)
www.americanbankingnews.com - August 22 at 8:26 PM
Neuralstem, Inc. (CUR) Issues  Earnings Results, Beats Expectations By $9.10 EPSNeuralstem, Inc. (CUR) Issues Earnings Results, Beats Expectations By $9.10 EPS
www.americanbankingnews.com - August 9 at 5:54 PM
Neuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business UpdateNeuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business Update
www.nasdaq.com - August 8 at 10:21 PM
Neuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business UpdateNeuralstem Reports Second Quarter 2017 Fiscal Results and Provides Clinical and Business Update
finance.yahoo.com - August 8 at 5:20 PM
Neuralstem reports 2Q lossNeuralstem reports 2Q loss
finance.yahoo.com - August 8 at 5:20 PM
Neuralstem Is Doomed - Neuralstem, Inc. (NYSEMKT:CUR ... - Seeking AlphaNeuralstem Is Doomed - Neuralstem, Inc. (NYSEMKT:CUR ... - Seeking Alpha
seekingalpha.com - August 3 at 7:03 PM
Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment ... - GlobeNewswire (press release)Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment ... - GlobeNewswire (press release)
globenewswire.com - August 2 at 11:34 PM
Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment ... - NasdaqNeuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment ... - Nasdaq
www.nasdaq.com - August 2 at 6:32 PM
Neuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic NeuropathyNeuralstem Awarded $~1MM Grant by NIH to Continue Preclinical Research into the Potential of NSI-189 for Treatment of Diabetic Neuropathy
finance.yahoo.com - August 2 at 6:32 PM
Mid-Day Market Update: ShoreTel Gains On Acquisition News ... - BenzingaMid-Day Market Update: ShoreTel Gains On Acquisition News ... - Benzinga
www.benzinga.com - July 28 at 7:29 PM
Mid-Day Market Update: ShoreTel Gains On Acquisition News; Neuralstem Shares PlungeMid-Day Market Update: ShoreTel Gains On Acquisition News; Neuralstem Shares Plunge
www.nasdaq.com - July 27 at 5:59 PM
Neuralstem Announces Pricing of Public Offering of Common Stock and WarrantsNeuralstem Announces Pricing of Public Offering of Common Stock and Warrants
finance.yahoo.com - July 27 at 5:59 PM
Neuralstem: NSI-189 Phase 2 Trial Fails To Meet Primary Efficacy EndpointNeuralstem: NSI-189 Phase 2 Trial Fails To Meet Primary Efficacy Endpoint
www.nasdaq.com - July 27 at 2:20 AM
After-Hours Movers 07/26: (AXTI) (NTGR) (FB) Higher; (CUR) (CYH) (BWLD) Lower (more...)After-Hours Movers 07/26: (AXTI) (NTGR) (FB) Higher; (CUR) (CYH) (BWLD) Lower (more...)
www.streetinsider.com - July 27 at 2:20 AM
Todays Research Reports on Stocks to Watch: Neuralstem and Flex PharmaToday's Research Reports on Stocks to Watch: Neuralstem and Flex Pharma
finance.yahoo.com - July 26 at 6:13 PM
Neuralstem Announces Proposed Public Offering of Common Stock and WarrantsNeuralstem Announces Proposed Public Offering of Common Stock and Warrants
finance.yahoo.com - July 26 at 6:13 PM
Positive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRXPositive Data IGNITEs TTPH, MDCO Makes A Good TANGO, Wait Continues For EGRX
www.rttnews.com - July 26 at 3:43 AM
Mid-Afternoon Market Update: Crude Oil Up 3%; Seagate Shares Drop After Q4 Miss - BenzingaMid-Afternoon Market Update: Crude Oil Up 3%; Seagate Shares Drop After Q4 Miss - Benzinga
www.benzinga.com - July 25 at 10:39 PM
UPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss - MarketWatchUPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss - MarketWatch
www.marketwatch.com - July 25 at 10:39 PM
Neuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive DisorderNeuralstem Announces Top-line Phase 2 Data of NSI-189 for Major Depressive Disorder
finance.yahoo.com - July 25 at 5:37 PM
UPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial missUPDATE: Neuralstem stock plummets 61% on news of mid-stage clinical trial miss
finance.yahoo.com - July 25 at 5:37 PM
ETFs with exposure to Neuralstem, Inc. : July 4, 2017ETFs with exposure to Neuralstem, Inc. : July 4, 2017
finance.yahoo.com - July 5 at 12:22 AM
Neuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive DisorderNeuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive Disorder
www.streetinsider.com - May 17 at 9:42 PM
Neuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive Disorder - StreetInsider.comNeuralstem (CUR) Completes Dosing in Phase 2 Trial of NSI-189 for Major Depressive Disorder - StreetInsider.com
www.streetinsider.com - May 17 at 4:41 PM

Social Media

Financials

Chart

Neuralstem (NASDAQ CUR) Chart for Saturday, November, 18, 2017
Loading chart…

This page was last updated on 11/18/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.